SGLT‐2 inhibitors may increase the risk of genital tract infections secondary to their mechanism of action23, 24, 25; however, investigation into these infections (eg urinalysis) may prompt further diagnostic workup and eventual diagnosis of bladder cancers that were present before initiation of SGLT‐2 inhibitor therapy. This evidence concerns the gene SLC5A2 and infection.